How do I find out if I qualify for a diffuse midline glioma, h3 k27m-mutant study in Minnesota?

Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.

Do I have to live in Minnesota to take part?

Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.

Does it cost anything to join a diffuse midline glioma, h3 k27m-mutant trial?

Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Clinical trials · Minnesota

Diffuse Midline Glioma, H3 K27M-Mutant clinical trials in Minnesota

We’re tracking 4 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.

Recruiting studies in Minnesota

NCT05077735RecruitingPhase 2
Split-course radiation for diffuse midline glioma
This trial tests a new way of giving radiation therapy for a type of brain tumor called diffuse midline glioma. It aims to see if splitting the radiation into smaller courses can help while reducing side effects.
Rochester, MinnesotaAges 1 year+
NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Minneapolis, MinnesotaAges 2–39
NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25
NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Minneapolis, MinnesotaAges 1–21

Where these studies are running in Minnesota

Institutions with a site for the recruiting diffuse midline glioma, h3 k27m-mutant studies listed above.

Children's Hospitals and Clinics of Minnesota - Minneapolis · 2 studies
Children's Hospital Minnesota
Mayo Clinic
University of Minnesota Masonic Cancer Center

What taking part in a diffuse midline glioma, h3 k27m-mutant study involves

A screening visit first

Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.

Care at a nearby site

Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.

You stay in control

Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.

The team decides eligibility

Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.

Diffuse Midline Glioma, H3 K27M-Mutant trials in other states

Common questions

Are there diffuse midline glioma, h3 k27m-mutant clinical trials in Minnesota?: Yes. We're currently tracking 4 recruiting diffuse midline glioma, h3 k27m-mutant studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
How do I find out if I qualify for a diffuse midline glioma, h3 k27m-mutant study in Minnesota?: Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
Do I have to live in Minnesota to take part?: Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
Does it cost anything to join a diffuse midline glioma, h3 k27m-mutant trial?: Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Not the right time?

New diffuse midline glioma, h3 k27m-mutant studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.

Get told when a study that fits you opens

Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.